PM2.5颗粒与COPD患者氧化应激水平及炎性因子的相关性

Correlation between PM2.5 particles and oxidative stress and inflammatory factors in COPD patients

目的探讨PM2.5颗粒与COPD患者氧化应激水平及炎性因子的相关性。方法选择86例COPD患者作为研究对象,根据其居住位置分组,郊区的患者为对照组,共42例,市区的患者为观察组,共44例,对两组患者肺功能、氧化应激水平(MDA、SOD)和炎性因子(IFN-γ、IL-6、IL-10、TNF-α、TGF-β)进行为期12周的监测,同时收集市区以及郊区各监控点的PM2.5实时数据,对比分析PM2.5颗粒与COPD患者氧化应激水平及炎性因子的相关性。结果本市市区空气PM2.5的含量明显高于郊区(P<0.05);郊区患者的FEV_1/FVC和FEV1指标明显高于市区患者;郊区患者的MDA和SOD水平明显低于市区;市区患者的IFN-γ、IL-6、IL-10、TNF-α和TGF-β含量明显高于郊区,差异均有统计学意义(P<0.05);PM2.5与氧化应激水平(MDA、SOD)呈正相关(r=0.413、0.806;P<0.05);PM2.5与炎性因子(TNF-α、IL-10、IL-6、IFN-γ、TGF-β)成正相关(r=0.521、0.476、0.432、0.513、0.496;P<0.05)。结论空气中PM2.5颗粒含量与COPD患者氧化应激水平及炎性因子均呈现正相关,可用于COPD的临床预防和诊疗。

Objective To investigate the relationship between PM2.5 granules and oxidative stress and inflammatory factors in COPD patients. Methods 86 patients were selected with COPD who were treated in our hospital from January 2016 to January 2017 as the subjects. According to their residential location group, suburban patients as the control group, a total of 42 cases, the urban area for the observation group, a total of 44 cases, the levels of lung function, oxidative stress (MDA, SOD) and inflammatory factors (IFN-γ, IL-6, IL-10, TNF-α, TGF-β) were monitored for 12 weeks. The PM2.5 real-time data of urban and suburban monitoring points were compared with those of COPD patients with oxidative stress and inflammatory factors. Results The content of PM2.5 in the urban area was significantly higher than that in the suburbs ( P <0.05). The FEV1 / FVC and FEV1 indexes in the suburbs were significantly higher than those in the urban patients ( P <0.05)( P <0.05). The levels of IFN-γ, IL-6, IL-10, TNF-α and TGF-β in urban patients were significantly higher than those in suburbs ( P <0.05)(TNF-α, IL-10, IL-6, IFN-γ, TGF-β) were positively correlated with the level of stress (MDA, SOD)( r =0.413,0.806;P <0.05)( R =0.521, 0.46, 0.432, 0.513, 0.496;P <0.05). Conclusion The content of PM2.5 in air is positively correlated with oxidative stress and inflammatory factors in patients with COPD, and can be used for clinical prevention and treatment of COPD.